April 02, 2025

Accelerated Onset of Aging-Related Diseases in Childhood Cancer Survivors?

In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases.

The ASCO Post

April 02, 2025

GLP-1 Spending Surged 500% Since 2018

U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.

Conexiant

April 01, 2025

Daily Physical Activity—Even at Light Intensities—May Reduce Cancer Risk

Investigators evaluated the risk of cancer among individuals who engaged in light- and moderate-to-vigorous–intensity physical activity daily.

The ASCO Post

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Cold Plunges: A Cellular Reset?

New research shows that 1 week of daily cold-water immersion enhances autophagy and reduces cell death signals.

Conexiant

March 31, 2025

Hormone Therapy Boosts Semaglutide Weight Loss

At 12 months, women on hormone therapy achieved 16% total body weight loss with semaglutide, compared to 12% in those not using hormone therapy, researchers reported.

Conexiant

March 28, 2025

Mango Intake Linked to Improved Insulin Sensitivity

Fasting insulin levels were significantly lower with mango intake, according to a new study.

Conexiant

March 28, 2025

T2D: Non-traditional CVD Risk Factors

Investigators identify and rank non-traditional risk factors for cardiovascular disease prediction.

Conexiant

March 28, 2025

AID Improves Glucose Control in Type 2 Diabetes, Study Shows

Automated insulin delivery (AID) reduced glycated hemoglobin by 0.9 percentage points in adults with type 2 diabetes, compared to 0.3 points in those who used continuous glucose monitoring methods alone.

Conexiant